BioWorld

July 9, 2003

Killer Clots That Attack Heart, Brain Countered By Clot-Busting Drugs Linked To Red Blood Cells

XOMA Regains Full Rights To Neuprex As Baxter Pulls Out

AEterna To Raise C$35.6M Upon Entering Bought-Deal Agreement

Other News To Note

Amgen Files With FDA Seeking Approval Of Enbrel In Psoriasis

Amgen Inc.'s Enbrel could be the first TNF blocker to make it to market as a treatment for psoriasis, an inflammatory disease often mischaracterized as a disease of the skin. (BioWorld Today) Read More

Genentech's Avastin Rights Outside U.S. Go To Roche

Today's news in brief

BioWorld

BioWorld briefs for July 15, 2026.

AI-generated illustration of a neuron with tau protein aggregation

AAIC 2026: Age of amyloid is being joined by time of tau

BioWorld

The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...

Celia trial: data strong, analysts skeptical

BioWorld

Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 14, 2026

Illustration of T cells attacking cancer

GABA signaling linked to immune resistance in some tumors

BioWorld

Certain cancers that contain organized clusters of immune cells known as tertiary lymphoid structures (TLS) do not respond to treatment as well as expected. Even...